PD-0325901
Contact us: [email protected]
EZSolution? PD-0325901, Sterile-Filtered |
1990-1 |
Biovision |
each |
EUR 326.4 |
PD-1/PD-L1 Inhibitor 2 |
B1050-25 |
Biovision |
each |
EUR 679.2 |
PD-1/PD-L1 Inhibitor 2 |
B1050-5 |
Biovision |
each |
EUR 242.4 |
PD-1/PD-L1 Inhibitor 1 |
B1213-25 |
Biovision |
each |
EUR 679.2 |
PD-1/PD-L1 inhibitor 2 |
B6023-25 |
ApexBio |
25 mg |
EUR 525.6 |
Description: PD-1/PD-L1 inhibitor 2 is a PD-1/PD-L1 interaction inhibitor. |
PD-1/PD-L1 inhibitor 2 |
B6023-5 |
ApexBio |
5 mg |
EUR 205.2 |
Description: PD-1/PD-L1 inhibitor 2 is a PD-1/PD-L1 interaction inhibitor. |
PD-1/PD-L1 inhibitor 1 |
B6172-25 |
ApexBio |
25 mg |
EUR 543.6 |
Description: IC50: 0.006-0.10 ?MPD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor.Plenty of studies show that blocking the PD-1/PD-Ll interactions can lead to the restorage and augment of T cell activation in many systems. |
PD-1/PD-L1 inhibitor 1 |
B6172-5 |
ApexBio |
5 mg |
EUR 201.6 |
Description: IC50: 0.006-0.10 ?MPD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor.Plenty of studies show that blocking the PD-1/PD-Ll interactions can lead to the restorage and augment of T cell activation in many systems. |
PD 151746 |
B4791-100 |
ApexBio |
100 mg |
EUR 714 |
Description: PD 151746 is a potent and selective inhibitor of calpain with Ki value of 0.26 ?M for ?-Calpain. Calpain is a calcium-dependent, non-lysosomal cysteine protease that expressed in mammals and many other organisms. |
PD 151746 |
B4791-25 |
ApexBio |
25 mg |
EUR 338.4 |
Description: PD 151746 is a potent and selective inhibitor of calpain with Ki value of 0.26 ?M for ?-Calpain. Calpain is a calcium-dependent, non-lysosomal cysteine protease that expressed in mammals and many other organisms. |
PD 151746 |
B4791-5 |
ApexBio |
5 mg |
EUR 142.8 |
Description: PD 151746 is a potent and selective inhibitor of calpain with Ki value of 0.26 ?M for ?-Calpain. Calpain is a calcium-dependent, non-lysosomal cysteine protease that expressed in mammals and many other organisms. |
PD 151746 |
B4791-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 151.2 |
Description: PD 151746 is a potent and selective inhibitor of calpain with Ki value of 0.26 ?M for ?-Calpain. Calpain is a calcium-dependent, non-lysosomal cysteine protease that expressed in mammals and many other organisms. |
PD 334581 |
B5727-10 |
ApexBio |
10 mg |
EUR 583.2 |
PD 334581 |
B5727-50 |
ApexBio |
50 mg |
EUR 2220 |
PD 173074 |
1675-100 |
Biovision |
each |
Ask for price |
PD 173074 |
27056 |
BPS Bioscience |
10 mg |
EUR 125 |
Description: PD 173074 inhibited the kinase activity of FGFR1 with an IC50 of 25 nM in vitro, while inhibiting Src, the receptors for insulin, epidermal growth factor (EGF) and PDGF, and several serine/threonine kinases with 1000-fold or higher IC50 values. PD 173074 was an ATP-competitive inhibitor of FGFR1, with a Ki of around 40 nM. PD 173074 inhibited autophosphorylation of FGFR1 and VEGFR2 in a dose-dependent manner with IC50s in the range of 1-5 nM and 100-200 nM, respectively. |
PD 184161 |
C4361-10 |
ApexBio |
10 mg |
EUR 339.6 |
Description: IC50: 10-100 nMPD 184161 is a MEK1/2 inhibitor. The intracellular signaling pathway of mitogen-activated protein kinases is involved in the regulation of various cellular functions. |
PD 184161 |
C4361-25 |
ApexBio |
25 mg |
EUR 673.2 |
Description: IC50: 10-100 nMPD 184161 is a MEK1/2 inhibitor. The intracellular signaling pathway of mitogen-activated protein kinases is involved in the regulation of various cellular functions. |
PD 184161 |
C4361-5 |
ApexBio |
5 mg |
EUR 217.2 |
Description: IC50: 10-100 nMPD 184161 is a MEK1/2 inhibitor. The intracellular signaling pathway of mitogen-activated protein kinases is involved in the regulation of various cellular functions. |
PD 166326 |
C3677-1 |
ApexBio |
1 mg |
EUR 193.2 |
Description: IC50: 8 nM for c-abl PD 166326 is a receptor tyrosine kinase inhibitor.Receptor tyrosine kinases are the high-affinity cell surface receptors for many growth factors, cytokines, as well as hormones. |
PD 166326 |
C3677-10 |
ApexBio |
10 mg |
EUR 1128 |
Description: IC50: 8 nM for c-abl PD 166326 is a receptor tyrosine kinase inhibitor.Receptor tyrosine kinases are the high-affinity cell surface receptors for many growth factors, cytokines, as well as hormones. |
PD 166326 |
C3677-5 |
ApexBio |
5 mg |
EUR 661.2 |
Description: IC50: 8 nM for c-abl PD 166326 is a receptor tyrosine kinase inhibitor.Receptor tyrosine kinases are the high-affinity cell surface receptors for many growth factors, cytokines, as well as hormones. |
PD 176252 |
B7122-10 |
ApexBio |
10 mg |
EUR 614.4 |
PD 198306 |
B7124-1 |
ApexBio |
1 mg |
EUR 151.2 |
Description: IC50: 8 nM for MEK [1]PD 198306 is a potent, selective and non-ATP competitive MAPK/ERK-kinase (MEK) inhibitor. MEK is a kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK). |
PD 198306 |
B7124-10 |
ApexBio |
10 mg |
EUR 634.8 |
Description: IC50: 8 nM for MEK [1]PD 198306 is a potent, selective and non-ATP competitive MAPK/ERK-kinase (MEK) inhibitor. MEK is a kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK). |
PD 198306 |
B7124-5 |
ApexBio |
5 mg |
EUR 381.6 |
Description: IC50: 8 nM for MEK [1]PD 198306 is a potent, selective and non-ATP competitive MAPK/ERK-kinase (MEK) inhibitor. MEK is a kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK). |
PD 135158 |
B7127-10 |
ApexBio |
10 mg |
EUR 583.2 |
PD 135158 |
B7127-50 |
ApexBio |
50 mg |
EUR 2220 |
PD 158780 |
B7130-10 |
ApexBio |
10 mg |
EUR 278.4 |
PD 158780 |
B7130-25 |
ApexBio |
25 mg |
EUR 543.6 |
PD 158780 |
B7130-5 |
ApexBio |
5 mg |
EUR 181.2 |
PD 118057 |
B7203-10 |
ApexBio |
10 mg |
EUR 400.8 |
PD 118057 |
B7203-50 |
ApexBio |
50 mg |
EUR 1491.6 |
PD 146176 |
B7208-10 |
ApexBio |
10 mg |
EUR 180 |
PD 146176 |
B7208-25 |
ApexBio |
25 mg |
EUR 344.4 |
PD 146176 |
B7208-50 |
ApexBio |
50 mg |
EUR 567.6 |
PD 173212 |
B7424-10 |
ApexBio |
10 mg |
EUR 634.8 |
PD 173212 |
B7424-5 |
ApexBio |
5 mg |
EUR 451.2 |
PD 173212 |
B7424-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 574.8 |
PD 161570 |
B7486-10 |
ApexBio |
10 mg |
EUR 544.8 |
PD 161570 |
B7486-50 |
ApexBio |
50 mg |
EUR 2056.8 |
PD 150606 |
A4413-25 |
ApexBio |
25 mg |
EUR 513.6 |
Description: PD 150606 is a specific inhibitor of calpain with Ki value of 0.21 ?M and 0.37 ?M for mu- and m- calpains, respectively [1]. |
PD 150606 |
A4413-5 |
ApexBio |
5 mg |
EUR 172.8 |
Description: PD 150606 is a specific inhibitor of calpain with Ki value of 0.21 ?M and 0.37 ?M for mu- and m- calpains, respectively [1]. |
PD 166793 |
A4438-10 |
ApexBio |
10 mg |
EUR 290.4 |
Description: Broad spectrum MMP inhibitor. Displays high affinity for MMP-2, -3 and -13 (IC50 values are 4, 7 and 8 nM respectively) and exhibits > 750-fold selectivity over MMP-1, -7 and -9. Attenuates left ventricular remodelling and dysfunction in rat model of heart failure. |
PD 166793 |
A4438-25 |
ApexBio |
25 mg |
EUR 597.6 |
Description: Broad spectrum MMP inhibitor. Displays high affinity for MMP-2, -3 and -13 (IC50 values are 4, 7 and 8 nM respectively) and exhibits > 750-fold selectivity over MMP-1, -7 and -9. Attenuates left ventricular remodelling and dysfunction in rat model of heart failure. |
PD 166793 |
A4438-5 |
ApexBio |
5 mg |
EUR 224.4 |
Description: Broad spectrum MMP inhibitor. Displays high affinity for MMP-2, -3 and -13 (IC50 values are 4, 7 and 8 nM respectively) and exhibits > 750-fold selectivity over MMP-1, -7 and -9. Attenuates left ventricular remodelling and dysfunction in rat model of heart failure. |
PD 81723 |
B6705-10 |
ApexBio |
10 mg |
EUR 340.8 |
PD 81723 |
B6705-50 |
ApexBio |
50 mg |
EUR 1245.6 |
PD 102807 |
B6821-10 |
ApexBio |
10 mg |
EUR 466.8 |
PD 102807 |
B6821-50 |
ApexBio |
50 mg |
EUR 1771.2 |
PD 160170 |
B6972-10 |
ApexBio |
10 mg |
EUR 408 |
PD 180970 |
A8606-10 |
ApexBio |
10 mg |
EUR 517.2 |
Description: ATP-competitive inhibitor of p210bcr/abl tyrosine kinase; selectively induces apoptosis in chronic myeloid leukemia (CML) K562 cells. Inhibits in vivo tyrosine phosphorylation of Gab2, CrkL and p210bcr/abl (IC50 values are 80, 80 and 170 nM respectively). |
PD 169316 |
A8689-10 |
ApexBio |
10 mg |
EUR 195.6 |
Description: IC50: A potent, selective and cell-permeable suppressor of p38 MAP kinase, with the IC50 value of 89 nM.PD169316, a specific p38 MAPK inhibitor, blocks signal transduction mediated by both TGF-? and Activin A, but not bone morphogenetic protein (BMP) 4. |
PD 169316 |
A8689-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 268.8 |
Description: IC50: A potent, selective and cell-permeable suppressor of p38 MAP kinase, with the IC50 value of 89 nM.PD169316, a specific p38 MAPK inhibitor, blocks signal transduction mediated by both TGF-? and Activin A, but not bone morphogenetic protein (BMP) 4. |
PD 169316 |
A8689-50 |
ApexBio |
50 mg |
EUR 595.2 |
Description: IC50: A potent, selective and cell-permeable suppressor of p38 MAP kinase, with the IC50 value of 89 nM.PD169316, a specific p38 MAPK inhibitor, blocks signal transduction mediated by both TGF-? and Activin A, but not bone morphogenetic protein (BMP) 4. |
PD 173074 |
A8253-10 |
ApexBio |
10 mg |
EUR 129.6 |
Description: PD173074 is a poten and selective fibroblast growth factor receptor (FGFR) inhibitor. Fibroblast growth factor-2 is reported to be able to induce proliferation and chemoresistance in Small cell lung cancer (SCLC) cells. |
PD 173074 |
A8253-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 142.8 |
Description: PD173074 is a poten and selective fibroblast growth factor receptor (FGFR) inhibitor. Fibroblast growth factor-2 is reported to be able to induce proliferation and chemoresistance in Small cell lung cancer (SCLC) cells. |
PD 173074 |
A8253-50 |
ApexBio |
50 mg |
EUR 254.4 |
Description: PD173074 is a poten and selective fibroblast growth factor receptor (FGFR) inhibitor. Fibroblast growth factor-2 is reported to be able to induce proliferation and chemoresistance in Small cell lung cancer (SCLC) cells. |
PD 173074 |
A8253-S |
ApexBio |
Evaluation Sample |
EUR 97.2 |
Description: PD173074 is a poten and selective fibroblast growth factor receptor (FGFR) inhibitor. Fibroblast growth factor-2 is reported to be able to induce proliferation and chemoresistance in Small cell lung cancer (SCLC) cells. |
PD 145305 |
C5830-10 |
ApexBio |
10 mg |
EUR 513.6 |
Description: PD 145305 is an inactive analog of PD 150606, a potent and selective calpains inhibitor [1]. Calpain is a class of cytosolic cysteine protease that is activated by elevated intracellular calcium. |
PD 145305 |
C5830-5 |
ApexBio |
5 mg |
EUR 315.6 |
Description: PD 145305 is an inactive analog of PD 150606, a potent and selective calpains inhibitor [1]. Calpain is a class of cytosolic cysteine protease that is activated by elevated intracellular calcium. |
PD 0332991 |
E1KS1116 |
EnoGene |
5mg |
EUR 812.4 |
PD-1:PD-L1 Homogeneous Assay Kit |
72014 |
BPS Bioscience |
384 rxns. |
EUR 1070 |
Description: The PD-1:PD-L1 Homogeneous Assay Kit is designed to measure the_x000D_inhibition of PD-1 binding to PD-L1. With this kit, only three simple steps on a microtiter_x000D_plate are required. First, a sample containing PD-1 and an inhibitor of choice is incubated with_x000D_the biotinylated PD-L1 for 60 minutes. Next, acceptor beads are added, then donor beads,_x000D_followed by reading the Alpha-counts. |
PD-1:PD-L2 Homogeneous Assay Kit |
72015 |
BPS Bioscience |
384 rxns. |
EUR 1070 |
Description: The PD-1:PD-L2 Homogeneous Assay Kit is designed to measure the_x000D_inhibition of PD-1 binding to PD-L2. With this kit, only three simple steps on a microtiter_x000D_plate are required. First, a sample containing PD-1 and an inhibitor of choice is incubated with_x000D_the biotinylated PD-L2 for 60 minutes. Next, acceptor beads are added, then donor beads,_x000D_followed by reading the Alpha-counts. |
PD-1:PD-L1 TR-FRET Assay |
72032 |
BPS Bioscience |
96 rxns. |
EUR 745 |
Description: The PD-1:PD-L1 TR-FRET Assay is designed to measure the inhibition of PD-1 binding to PD-L1 in a homogeneous 96 reaction format. This FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; a sample containing europium-labeled (Eu) PD-1, dye-labeled acceptor, biotin-labeled PD-L1, and an inhibitor is incubated for two hours. Then, the fluorescence intensity is measured using a fluorescence reader. |
PD-1:PD-L1 TR-FRET Assay |
72038 |
BPS Bioscience |
384 rxns. |
EUR 845 |
Description: The PD-1:PD-L1 TR-FRET Assay is designed to measure the inhibition of PD-1 binding to PD-L1 in a homogeneous 384 reaction format. This FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; a sample containing europium-labeled (Eu) PD-1, dye-labeled acceptor, biotin-labeled PD-L1, and an inhibitor is incubated for two hours. Then, the fluorescence intensity is measured using a fluorescence reader. |
PD-1:PD-L1/PD-L2 Cell-Based Inhibitor Screening Assay Kit |
60800 |
BPS Bioscience |
96 rxns. |
EUR 1070 |
Description: The PD-1/PD-L1 Inhibitor Screening Cell-Based Assay is a bioluminescent cell-based assay that can be used to screen and profile inhibitors of PD-1:PD-L1 or PD-1:PD-L2 interaction. The assay consists of two main components:_x000D_ • PD-1 Effector cells (PD-1/NFAT reporter-Jurkat cells): Reporter Jurkat T cells expressing firefly luciferase gene under the control of NFAT response elements and also constitutively expressing human PD-1. These cryopreserved cells are provided in a thaw-and-use format that does not require cell propagation._x000D_ • _x000D_Expression vectors for TCR activator, human PD-L1, and human PD-L2: Transfection-ready vectors are used to transfect cells to create the target cells that overexpress PD-L1 or PD-L2 and an engineered cell surface T cell receptor (TCR) activator._x000D_ |
PD-1:PD-L2 TR-FRET Assay Kit |
72012 |
BPS Bioscience |
384 rxns. |
EUR 1070 |
Description: The PD-1:PD-L2 TR-FRET Assay Kit is designed to measure the inhibition of PD-1 binding to_x000D_PD-L2 in a homogeneous 384 reaction format. Cell signaling through the PD-1 receptor upon_x000D_binding the PD-L2 ligand attenuates immune responses and is exploited by both tumors and_x000D_viruses. This FRET-based assay requires no time-consuming washing steps, making it_x000D_especially suitable for high throughput screening applications. The assay procedure is_x000D_straightforward and simple; a sample containing europium-labeled (Eu) PD-1, dye-labeled_x000D_acceptor, biotin-labeled PD-L2, and an inhibitor is incubated for two hours. Then, the_x000D_fluorescence intensity is measured using a fluorescence reader. |
PD-1[Biotinylated]:PD-L1 Homogeneous Assay Kit |
72028 |
BPS Bioscience |
384 rxns. |
EUR 1070 |
Description: The PD-1[Biotinylated]:PD-L1 Homogeneous Assay Kit is designed to measure_x000D_the inhibition of PD-1 binding to PD-L1. The PD-1[Biotinylated]:PD-L1 Homogeneous Assay Kit_x000D_comes in a convenient AlphaLISA® format with purified biotinylated PD-1, FLAG-tagged PD-L1,_x000D_and assay buffer to perform a total of 384 reactions. With this kit, only three simple steps on a_x000D_microtiter plate are required. First, a sample containing biotinylated PD-1 and an inhibitor of_x000D_choice is incubated with the FLAG-tagged PD-L1 for 60 minutes. Next, acceptor beads are_x000D_added, then donor beads, followed by reading the Alpha-counts. |
Ribosome-inactivating protein PD-L1 / PD-L2 Antibody |
20-abx319445 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Ribosome-inactivating protein PD-L1/PD-L2 Antibody |
1-CSB-PA306294LA01PJJ |
Cusabio |
|
|
|
Description: A polyclonal antibody against Ribosome-inactivating protein PD-L1/PD-L2. Recognizes Ribosome-inactivating protein PD-L1/PD-L2 from Phytolacca dioica. This antibody is Unconjugated. Tested in the following application: ELISA |
PD-L1 Protein |
20-abx261703 |
Abbexa |
-
EUR 4101.60
-
EUR 393.60
-
EUR 276.00
|
|
|
PD-L1 Protein |
20-abx263458 |
Abbexa |
-
EUR 1930.80
-
EUR 393.60
-
EUR 276.00
|
|
|
PD-ECGF Antibody |
abx236264-100ug |
Abbexa |
100 ug |
EUR 661.2 |
|
PD-166285 dihydrochloride |
B2094-25 |
Biovision |
each |
EUR 757.2 |
PD-166285 dihydrochloride |
B2094-5 |
Biovision |
each |
EUR 235.2 |
PD-L1 (CD274) |
100443-1 |
BPS Bioscience |
100 µg |
EUR 320 |
Description: Human secreted Programmed Cell Death 1 Ligand 1 (PD-L1) protein, also known as CD274, PDCD1L1, and B7 homolog 1 (B7-H1), GenBank Accession No. NM_014143, a.a. 19-239, expressed in an E. coli expression system. MW = 25 kDa. |
PD-L1 (CD274) |
100443-2 |
BPS Bioscience |
1 mg |
EUR 2720 |
Description: Human secreted Programmed Cell Death 1 Ligand 1 (PD-L1) protein, also known as CD274, PDCD1L1, and B7 homolog 1 (B7-H1), GenBank Accession No. NM_014143, a.a. 19-239, expressed in an E. coli expression system. MW = 25 kDa. |
PD 153035 Hydrochloride |
1656-2 |
Biovision |
each |
EUR 189.6 |
PD-1 Antibody |
24505-100ul |
SAB |
100ul |
EUR 468 |
PD-1 Antibody |
24506-100ul |
SAB |
100ul |
EUR 468 |
EZSolution? PD 98059 |
1783-5 |
Biovision |
each |
EUR 189.6 |
PD 98059, >99% |
BC064-010 |
GenDepot |
10mg |
EUR 278.4 |
PD 98059, >99% |
BC064-025 |
GenDepot |
25mg |
EUR 360 |
PD 98059, >99% |
BC064-050 |
GenDepot |
50mg |
EUR 537.6 |
PD 144418 oxalate |
B7125-10 |
ApexBio |
10 mg |
EUR 408 |
PD 144418 oxalate |
B7125-50 |
ApexBio |
50 mg |
EUR 1531.2 |
PD 168568 dihydrochloride |
B7420-10 |
ApexBio |
10 mg |
EUR 369.6 |
PD 168568 dihydrochloride |
B7420-50 |
ApexBio |
50 mg |
EUR 1363.2 |
PD 0332991 (Palbociclib) |
B7798-25 |
ApexBio |
25 mg |
EUR 184.8 |
Description: PD-0332991 is selective and oral inhibitor of cyclin-dependent kinase 4/6 with IC50 values of 11nM and 16nM, respectively for CDK4 and CDK6 [1].PD-0332991 is a highly specific inhibitor of CDK4/6. |
PD 0332991 (Palbociclib) |
B7798-5 |
ApexBio |
5 mg |
EUR 129.6 |
Description: PD-0332991 is selective and oral inhibitor of cyclin-dependent kinase 4/6 with IC50 values of 11nM and 16nM, respectively for CDK4 and CDK6 [1].PD-0332991 is a highly specific inhibitor of CDK4/6. |
PD 0332991 (Palbociclib) |
B7798-S |
ApexBio |
Evaluation Sample |
EUR 97.2 |
Description: PD-0332991 is selective and oral inhibitor of cyclin-dependent kinase 4/6 with IC50 values of 11nM and 16nM, respectively for CDK4 and CDK6 [1].PD-0332991 is a highly specific inhibitor of CDK4/6. |
PD-L1 Antibody |
4059-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response (1). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (2,3). Through a yet unknown activating receptor, it may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (4). |
PD-L1 Antibody |
4059-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response (1). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (2,3). Through a yet unknown activating receptor, it may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (4). |
PD-L1 Peptide |
4059P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (IN) PD-L1 peptide |
PD-L2 Antibody |
4063-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: PD-L2 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by co gnate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2, both of which are thought act as a negative regulator of T cell activation. However, it has been suggested that PD-L2 can act to stimulate an immunogenic response through and alternative receptor from PD-1. |
PD-L2 Antibody |
4063-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: PD-L2 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by co gnate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2, both of which are thought act as a negative regulator of T cell activation. However, it has been suggested that PD-L2 can act to stimulate an immunogenic response through and alternative receptor from PD-1. |
PD-L2 Peptide |
4063P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (IN) PD-L2 peptide |
PD-1 Antibody |
4065-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. |
PD-1 Antibody |
4065-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. |
PD-1 Peptide |
4065P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (CT) PD-1 peptide |
PD-1 Antibody |
4067-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. |
PD-1 Antibody |
4067-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. |
PD-1 Peptide |
4067P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (IN) PD-1 peptide |
PD 123319 ditrifluoroacetate |
A3704-10 |
ApexBio |
10 mg |
EUR 250.8 |
Description: Description:IC50 Value: 1.2 ±0.4 mM (Inhibition of adenylyl cyclase elicited by 0.1 microM Ang II) [2]PD 123319 ditrifluoroacetate is a potent, selective, non-peptide angiotensin AT2 receptor antagonist. |
PD 123319 ditrifluoroacetate |
A3704-25 |
ApexBio |
25 mg |
EUR 489.6 |
Description: Description:IC50 Value: 1.2 ±0.4 mM (Inhibition of adenylyl cyclase elicited by 0.1 microM Ang II) [2]PD 123319 ditrifluoroacetate is a potent, selective, non-peptide angiotensin AT2 receptor antagonist. |
PD 123319 ditrifluoroacetate |
A3704-5 |
ApexBio |
5 mg |
EUR 205.2 |
Description: Description:IC50 Value: 1.2 ±0.4 mM (Inhibition of adenylyl cyclase elicited by 0.1 microM Ang II) [2]PD 123319 ditrifluoroacetate is a potent, selective, non-peptide angiotensin AT2 receptor antagonist. |
PD 123319 ditrifluoroacetate |
A3704-50 |
ApexBio |
50 mg |
EUR 787.2 |
Description: Description:IC50 Value: 1.2 ±0.4 mM (Inhibition of adenylyl cyclase elicited by 0.1 microM Ang II) [2]PD 123319 ditrifluoroacetate is a potent, selective, non-peptide angiotensin AT2 receptor antagonist. |
PD 168077 maleate |
B6578-10 |
ApexBio |
10 mg |
EUR 362.4 |
PD 168077 maleate |
B6578-50 |
ApexBio |
50 mg |
EUR 1315.2 |
PD-L1 Antibody |
49251-100ul |
SAB |
100ul |
EUR 399.6 |
PD-L1 Antibody |
49251-50ul |
SAB |
50ul |
EUR 286.8 |
PD-L1 Peptide |
46-156P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: CD274 / PD-L1 Peptide |
PD-123319 ditrifluoroacetate |
9640-25 |
Biovision |
each |
EUR 757.2 |
PD-123319 ditrifluoroacetate |
9640-5 |
Biovision |
each |
EUR 235.2 |
PD-0332991 isethionate |
9480-25 |
Biovision |
each |
EUR 652.8 |
PD-0332991 isethionate |
9480-5 |
Biovision |
each |
EUR 210 |
Anti-PD-L1 |
DB-241-0.1 |
DB Biotech |
100 μl |
EUR 469.2 |
Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated |
Anti-PD-L1 |
DB-241-0.2 |
DB Biotech |
200 μl |
EUR 675.6 |
Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated |
Anti-PD-L1 |
DB-241-0.5 |
DB Biotech |
500 μl |
EUR 889.2 |
Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated |
Anti-PD-L1 |
DB-241-1 |
DB Biotech |
1 ml |
EUR 1450.8 |
Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated |
Anti-PD-L1 |
DB-241-RTU-15 |
DB Biotech |
15 ml |
EUR 813.6 |
Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use) |
Anti-PD-L1 |
DB-241-RTU-7 |
DB Biotech |
7 ml |
EUR 519.6 |
Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use) |
Anti-PD-L1 |
DB241-RTU-15 |
DB Biotech |
15 ml |
EUR 813.6 |
Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use) |
Anti-PD-L1 |
DB241-RTU-7 |
DB Biotech |
7 ml |
EUR 519.6 |
Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use) |
PD-1 Antibody |
P1001-01m |
SAB |
0.1m |
EUR 198 |
PD-1 Antibody |
P1001-1ml |
SAB |
1ml |
EUR 451.2 |
PD-L1 Antibody |
P1013-01m |
SAB |
0.1m |
EUR 224.4 |
PD-L1 Antibody |
P1013-1ml |
SAB |
1ml |
EUR 807.6 |
PD-1,CD279 |
E6TA00107 |
EnoGene |
0.1mg |
EUR 411.6 |
PD-L1, CD274 |
E6TA00108 |
EnoGene |
0.1mg |
EUR 411.6 |
PD-L1 Antibody |
R31573 |
NSJ Bioreagents |
100 ug |
EUR 356.15 |
Description: Programmed death-ligand 1, also known as CD274 or B7-H1 is a protein that in humans is encoded by the CD274 gene. It is a 33-70kDa type 1 transmembrane protein that has been speculated to play a major role in suppressing the immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis. Upregulation on tumor MDCs downregulates T-cell immunity and PD-L1 blockade may represent an approach for cancer immunotherapy. It can provide positive costimulatory signals for innate and adaptive immunity and for protection against intracellular bacterial infection. It has been found that PD1/PDL1 pathway may be a good target for restoring antitumor immunity in ovarian cancer. |
PD-L1 Antibody |
R33263-100UG |
NSJ Bioreagents |
100 ug |
EUR 339.15 |
Description: Additional name(s) for this target protein: Programmed cell death 1 ligand 1; CD274 |
PD-0325901